Tirzepatide 15 mg Max: Zepbound's FDA-Approved Target Dose (20.9% Mean Weight Loss)
The FDA-approved 15 mg weekly dose is Zepbound's target maintenance — where SURMOUNT-1 measured its 20.9% mean body weight reduction, the strongest non-surgical weight-loss outcome ever published.
Tirzepatide 15 mg weekly is the FDA-approved maximum dose for both Zepbound (chronic weight management) and Mounjaro (type 2 diabetes). It's where SURMOUNT-1 NEJM 2022 measured its 20.9% mean body-weight reduction at 72 weeks — the strongest weight-loss outcome ever produced in a randomized non-surgical trial. Patients reach 15 mg at week 21 after standard titration and typically maintain at this dose long-term.
SURMOUNT-1 detailed outcomes at 15 mg
| Outcome | Tirzepatide 15 mg | Placebo |
|---|---|---|
| Mean weight loss (72 wks) | 20.9% | 3.1% |
| % losing ≥5% | 91% | 35% |
| % losing ≥10% | 78% | 14% |
| % losing ≥15% | 57% | 3% |
| % losing ≥20% | 36% | <1% |
For a 200 lb starting weight, 20.9% mean weight loss equals ~42 lbs. 78% of 15 mg participants lost at least 20 lbs; 36% lost at least 40 lbs. SURMOUNT-1 also reported cardiovascular and metabolic improvements: SBP −8.6 mm Hg, HbA1c −0.51%, waist circumference −18.5 cm, fasting triglycerides −27.6%, hsCRP −41.7%.
Reaching 15 mg: titration timeline
| Weeks | Dose | Purpose |
|---|---|---|
| 1-4 | 2.5 mg | Starter |
| 5-8 | 5 mg | First therapeutic |
| 9-12 | 7.5 mg | Mid-range |
| 13-16 | 10 mg | Mid-high |
| 17-20 | 12.5 mg | Sub-max |
| 21+ | 15 mg | Target maintenance |
Side effect profile at 15 mg
From SURMOUNT-1: nausea 39%, diarrhea 23%, vomiting 17%, constipation 17%, abdominal pain ~12%. Most are mild-to-moderate and decrease over time. Severe AEs at 15 mg are uncommon but can require dose reduction or discontinuation. Pancreatitis is rare — sustained abdominal pain warrants clinician evaluation.
Long-term maintenance at 15 mg
SURMOUNT-4 (Aronne et al, JAMA 2024) showed that patients who reached 10-15 mg and continued treatment maintained their weight loss at 88 weeks (~21 months) — while patients randomized to withdraw to placebo regained roughly half their lost weight over 52 weeks. Continuous treatment at maximum dose is the intended use pattern for Zepbound chronic weight management.
Get to 15 mg tirzepatide with Trimi
$125/month annual plan covers full 21-week titration from 2.5 mg starter through 15 mg target maintenance. Same active ingredient as Zepbound.
Start your visitFAQs
Is 15 mg the maximum tirzepatide dose?
Yes — 15 mg weekly is the FDA-approved maximum for both Zepbound (chronic weight management) and Mounjaro (type 2 diabetes). There is no FDA-approved higher dose. Per Zepbound prescribing information, 15 mg is the target maintenance dose for patients seeking maximum weight-loss effect.
What weight loss does 15 mg produce?
SURMOUNT-1 NEJM 2022: 20.9% mean body weight reduction at 72 weeks on tirzepatide 15 mg vs 3.1% on placebo. 91% of patients lost ≥5%; 78% lost ≥10%; 57% lost ≥15%; 36% lost ≥20%. This is the strongest weight-loss outcome ever published for a non-surgical intervention in obesity medicine.
When do I reach 15 mg?
Week 21 per the standard titration. Tirzepatide titration: 2.5 mg (wks 1-4) → 5 mg (wks 5-8) → 7.5 mg (wks 9-12) → 10 mg (wks 13-16) → 12.5 mg (wks 17-20) → 15 mg (wks 21+ target maintenance). Total titration time from start to 15 mg is 5 months.
Can I stay at 15 mg long-term?
Yes — that's the intended use as Zepbound's target maintenance dose. SURMOUNT-4 (Aronne et al, 2024) showed maintained weight loss at 88 weeks on continuous 10-15 mg dosing. Real-world clinicians keep responding patients at 15 mg indefinitely as long as tolerance and outcomes remain good.
Side effects at 15 mg vs 10 mg?
From SURMOUNT-1: nausea 39% at 15 mg vs 33% at 10 mg, diarrhea 23% vs 21%, vomiting 17% vs 14%, constipation 17% vs 17%. The 15 mg dose produces slightly more frequent and intense GI symptoms than 10 mg, but most are mild-to-moderate. Severe symptoms warrant either dropping back to 12.5 mg or pausing per clinician guidance.
Should I escalate from 12.5 mg to 15 mg?
Depends on response and tolerance. If you've plateaued at 12.5 mg with steady appetite suppression but want additional weight loss, 15 mg is the standard next step. If you're losing well and tolerating side effects at 12.5 mg, holding may be reasonable. The 12.5 → 15 mg jump produces a smaller marginal benefit than earlier titration steps.
What about 'Ozempic face' at 15 mg tirzepatide?
Risk is highest at 15 mg because rate of weight loss is fastest. Patients concerned about facial volume loss can: (1) escalate to 15 mg but maintain extra protein (1.4-1.6 g/kg) and resistance training, (2) hold at 10 or 12.5 mg sub-max maintenance, or (3) escalate but use deliberate caloric intake to slow rate of loss.
Related reading
Disclaimer: Informational, not medical advice. Trial citations: Jastreboff AM et al, NEJM 2022 (SURMOUNT-1); Aronne LJ et al, JAMA 2024 (SURMOUNT-4). Compounded tirzepatide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. **The FDA does not review or approve any compounded medications for safety or effectiveness.